Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 901–1,000 of 1,004
Zhou, Z., Shen, J., Zhao, M., Zhang, X., Wang, T., Li, J., & Zhao, X. (2023) · BMC Public Health · doi:10.1186/s12889-023-15118-8 · Cited by 6
“The main local and systemic adverse reactions of COVID19 vaccine are mild or moderate in severity [12, 13].”
BackgroundPre-clinical models to define correlates of protection for SARS-CoV-2
Brady, C., Tipton, T., Longet, S., & Carroll, M. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166664 · Cited by 6
“Augmented levels of circulating CD8+ T cells were detected in mice vaccinated with BNT162b2 versus BNT162b1, likely due to the broader range of T cell epitopes encoded by the BNT162b2 candidate.”
BackgroundInfluentialRatajczak, P., Banach, Z., Kopciuch, D., Paczkowska, A., Zaprutko, T., Krawczyk, J., Maciuszek-Bartkowska, B., & Kus, K. (2023) · Healthcare · doi:10.3390/healthcare11111532 · Cited by 6
“The AEs assessment included eight articles: four concerning BNT162b2 [14,15,19,20] and four concerning mRNA-1273 [16–18,21], which were additionally divided according to symptoms after the first and second doses of the vaccines.”
BackgroundMahase, E. (2021) · BMJ · doi:10.1136/bmj.n1920 · Cited by 6
The Delta Variant Had Negligible Impact on COVID-19 Vaccine Effectiveness in the USAPreprint
Blaiszik, B. J., Graziani, C., Olds, J. L., & Foster, I. T. (2021) · medRxiv · doi:10.1101/2021.09.18.21263783 · Cited by 7
Pandemic preparation without romance: insights from public choice
Tabarrok, A. T. (2025) · Public Choice · doi:10.1007/s11127-025-01277-2 · Cited by 6
Syrimi, N., Sourri, F., Giannakopoulou, M.-C., Karamanis, D., Pantousas, A., Georgota, P., Rokka, E., Vladeni, Z., Tsiantoula, E., Soukara, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093172 · Cited by 5
“Studies have shown that mRNA COVID-19 vaccines had similar efficacy among obese and non-obese individuals [1,16,89], while others report a decreased antibody response to the first dose of BNT162b2 COVID-19 vaccine in the obesity or pre-obesity group [62,95].”
Covid-19 A Comprehensive Review of Signs, Symptoms, Diagnosis, and Treatment Strategies
Vishal, M. K., U, P. W. S., & Kodage, P. B. (2024) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-18110 · Cited by 5
Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis
Rai, S., & Tripathi, S. S. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_750_2024 · Cited by 6
Gallinaro, A., Falce, C., Pirillo, M. F., Borghi, M., Grasso, F., Canitano, A., Cecchetti, S., Baratella, M., Michelini, Z., Mariotti, S., et al. (2025) · Vaccines · doi:10.3390/vaccines13030216 · Cited by 5
“However, several studies have reported that the levels of vaccine-induced neutralizing antibodies (nAbs) declined over time [12] and that they were less effective against the subsequent variants of concern (VoCs), owing to increased transmissibility and a higher ability to evade the immune response…”
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery
Lam, J. H., Sinsinbar, G., Loo, S. Y., Chia, T. W., Lee, Y. J., Fong, J. Y., Chia, Y. E., Penna, R. R., Liu, S., Pascolo, S., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01820 · Cited by 5
Levi, R., Mansuri, F., Jordán, M., & Ladapo, J. A. (2026) · Global Epidemiology · doi:10.1101/2025.04.25.25326460 · Cited by 5
Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism
Dinesh, R. K., Wang, C., Qu, Y., Rustagi, A., Cousins, H. C., Zengel, J. R., Wang, X., Barnard, T. R., Johnson, W. A., Xu, G., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013157 · Cited by 5
“Similarly, current COVID-19 vaccines are highly effective in preventing symptomatic illness and function by triggering an immune response against the Spike protein [17].”
The seven enigmas of SARS-CoV-2: From the past to the future
Andreakos, E., Arkin, L. M., Bastard, P., Bolze, A., Borghesi, A., Brodin, P., Casanova, J., Casari, G., Cobat, A., Drolet, B. A., et al. (2025) · Journal of Human Immunity · doi:10.70962/jhi.20250149 · Cited by 5
“Despite the efficacy of RNA vaccines (160, 177), the human genetic and immunological determinants of critical breakthrough cases remained unclear, especially in patients with normal antibody responses to the vaccine.”
Grabowski, J., Niebrzydowska, A., Brzozowska, A., Waszak, P. M., Zagożdżon, P., Ali, S., Brancewicz, T., Wolff, M., Macul-Sanewska, A., & Bidzan, L. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10110320 · Cited by 5
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01431-x · Cited by 6
A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants
Zhang, Y., Feng, M., He, Y., Liu, F., & Ma, R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966847 · Cited by 6
Tan, S. Y., Teo, S. P., Abdullah, M. S., Chong, P. L., Asli, R., Mani, B. I., Momin, N. R., Lim, A. C. A., Rahman, N. A., Chong, C. F., et al. (2022) · Western Pacific surveillance response journal · doi:10.5365/wpsar.2022.13.4.941 · Cited by 6
Design of effective outpatient sentinel surveillance for COVID-19 decision-making: a modeling study
Toh, K. B., Runge, M., Richardson, R. A. K., Hladish, T. J., & Gerardin, J. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08261-5 · Cited by 5
Ma, Q., Huang, F., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Life · doi:10.3390/life13061304 · Cited by 6
“BNT162b2 contains mRNA encoding a full-length stable S glycoprotein that elicits dose-dependent SARS-CoV-2 neutralizing antibody titers [11].”
BackgroundDrug delivery breakthrough technologies – A perspective on clinical and societal impact
Bittner, B., Sánchez-Félix, M., Lee, D., Koynov, A. A., Horvath, J. D., Schumacher, F. F., & Matoori, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.034 · Cited by 5
Pace, V. D., Bruzzone, B. M., Ricucci, V., Calcavecchia, N., Guarona, G., Giberti, I., Costa, E., Ogliastro, M., Galano, B., Nigro, N., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2258632 · Cited by 5
Hollstein, M. M., Dierks, S., Schön, M. P., Bergmann, A., Abratis, A., Eidizadeh, A., Kaltenbach, S., Schanz, J., Groß, U., Leha, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29122 · Cited by 5
“6,8 11 They are highly potent in activating the T ‐ cell response, 12 which is particularly important for antiviral activity.”
BackgroundLapinsky, S. C., Baxter, N. N., Sutradhar, R., Everett, K., Porter, J., Kwong, J. C., Fell, D. B., Snelgrove, J. W., Campbell, D. M., & Simpson, A. N. (2023) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2023.102239 · Cited by 5
Hossaini, S., Keramat, F., Cheraghi, Z., Zareie, B., & Doosti‐Irani, A. (2023) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2023.128 · Cited by 6
Reiter, L., Greffrath, J., Zidel, B., Ostrowski, M., Gommerman, J. L., Madhi, S. A., Tran, R., Martín‐Orozco, N., Panicker, R. K. G., Cooper, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55320-1 · Cited by 5
Guo, J., Luo, Y., Ma, Y., Xu, S., Li, J., Wang, T., Lei, L., He, L., Yu, H., & Xie, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1368876 · Cited by 5
Ideguchi, S., Miyagi, K., Kami, W., Tasato, D., Higa, F., Maeshiro, N., Nagamine, S., Nakamura, H., Kinjo, T., Nakamatsu, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309808 · Cited by 5
“The SARS-CoV-2 vaccine attenuates the effects of infection, hospitalization risk, and COVID-19 severity depending on the time since vaccination, which may have influenced the results of this study [34–36].”
ResultGentilini, P., Lindsay, J. C., Konishi, N., Fukushima, M., & Polykretis, P. (2026) · Oncotarget · doi:10.18632/oncotarget.28827 · Cited by 5
Molecular accuracy vs antigenic speed: SARS-CoV-2 testing strategies
Fajardo, Á., Perbolianachis, P., Ferreiro, I., Moreno, P., & Moratorio, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.12.006 · Cited by 5
Matsunaga, H., Takeuchi, H., Oba, Y., Fujimi, S., Honda, T., & Tomonaga, K. (2022) · Vaccines · doi:10.3390/vaccines10020177 · Cited by 6
Giugliano, F., Zucali, P. A., Galli, G., Ballatore, Z., Corti, C., Aliaga, P. T., Uliano, J., Vivanet, G., Curigliano, G., Conforti, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.011 · Cited by 5
“The rate and the spectrum of G1/G2-reported AE was consistent with those reported in the general population [7-9].”
Esposito, S., & the Pediatricians of Emilia-Romagna Region, I. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01229-2 · Cited by 5
“We also know from the data on adults that the vaccine’s ability to prevent hospitalizations and deaths is much greater than its ability to prevent infection: therefore, vaccination can avoid all or almost all serious cases, including worrying ones [15].”
BackgroundHollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Dierks, S., Schaffrinski, M., Zachmann, K., et al. (2022) · Allergy · doi:10.1111/all.15373 · Cited by 5
Islam, Z., Yamamoto, S., Mizoue, T., Tanaka, A., Oshiro, Y., Inamura, N., Konishi, M., Ozeki, M., Sugiura, W., & Ohmagari, N. (2022) · Vaccines · doi:10.3390/vaccines10050776 · Cited by 5
“Randomized controlled trials [6,7] have reported that COVID-19 vaccines are highly effective in preventing COVID-19, irrespective of diabetes status.”
BackgroundBrain Gene Silencing with Cationic Amino-Capped Poly(ethylene glycol) Polyplexes
Uchegbu, I. F., Alamoudi, A. A., Workman, D. G., Workman, D. G., Uchegbu, I. F., & Uchegbu, I. F. (2022) · Biomedicines · doi:10.3390/biomedicines10092182 · Cited by 5
“The recent approval of both mRNA vaccines [1] and gene silencing therapeutics [2] has demonstrated that nucleic acid based therapeutics may be exploited for a wide variety of applications.”
BackgroundPrediction of COVID-19 infection spread through agent-based simulation
An, T., Kim, H., & Joo, C. (2022) · ACM International Symposium on Theory, Algorithmic Foundations, and Protocol Design for Mobile Networks and Mobile Computing (MobiHoc) · doi:10.1145/3492866.3557735 · Cited by 5
Sehrawat, S., Osterrieder, N., Schmid, D. S., & Rouse, B. T. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105078 · Cited by 7
“All rights reserve mRNA vaccines proved remarkably effective at preventing serious disease and at reducing transmission rates [1,2].”
Conducting Goals of Care Conversations: Lessons From the COVID-19 Pandemic
Lai, A. T., & Abdullah, N. (2023) · Journal of Palliative Care · doi:10.1177/08258597231153386 · Cited by 5
“This is in contrast to later waves of COVID-19 when therapeutics, 24,25 vaccine development, 26 – 28 and variant strains 29 altered the illness trajectory of patients with COVID-19 to that with less morbidity and mortality.”
ResultRenna, L. V., Bertani, F., Podio, A., Boveri, S., Carrara, M., Pinton, A., Milani, V., Spuria, G., Nizza, A. F., Basilico, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11020463 · Cited by 5
Fernandes, E. R., Taminato, M., Apostólico, J. D. S., Gabrielonni, M. C., Lunardelli, V. A. S., Maricato, J. T., Andersen, M. L., Tufik, S., & Rosa, D. S. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100083 · Cited by 5
Amellal, H., Assaid, N., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100288 · Cited by 5
Atri, H., Teka, H., & Kouki, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15332 · Cited by 5
Katoto, P. D., Kakubu, M. A., Tamuzi, J. L., Brand, A., Ayuk, A. C., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2204154 · Cited by 5
“Serious adverse effects were uncommon in randomized clinical trials (RCTs) involving adolescents, and young adults participants, and vaccination effectiveness was near to 100% [13,14].”
BackgroundBroly, H., Souquet, J., & Beck, A. (2023) · mAbs · doi:10.1080/19420862.2023.2220150 · Cited by 5
Hou, C., Williams, S. A., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072627 · Cited by 5
Arbel, A., Bishara, H., Barnett‐Griness, O., Cohen, S., Najjar‐Debbiny, R., Gronich, N., Auriel, E., & Saliba, W. (2023) · European Journal of Neurology · doi:10.1111/ene.16025 · Cited by 5
“However, those trials were under-powered regarding rare adverse events [1, 2].”
BackgroundOspina, A. V., Bruges, R. E., Triana, I. C., Sánchez, G., Barrero, A., Mantilla, W. A., Ramos, P., Bernal, L., Aruachán, S., González, M., et al. (2023) · Journal of Cancer · doi:10.7150/jca.79969 · Cited by 5
“Ben-Aharon and colleagues studied the effectiveness of the BNT162b2 vaccine in a cohort of cancer patients (n=232) compared with a previously healthy control group of health workers (n=261).”
InfluentialErice, A., Prieto, L., & Caballero, C. (2023) · Vaccines · doi:10.3390/vaccines11121835 · Cited by 5
“On longer-term follow-up, the vaccine efficacy decreased to 84% within 7 months [2,3], due to waning immunity and the emergence of variants with the capacity to evade vaccine-induced protection [4,5].”
BackgroundViral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic
Lamothe, P. A., Capric, V., & Lee, F. E.-H. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001061 · Cited by 5
Wan, E. Y. F., Wang, B., Lee, A. L., Zhou, J., Chui, C. S. L., Lai, F. T. T., Li, X., Wong, C. K. H., Hung, I. F., Lau, C. S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107149 · Cited by 5
Echevarria, F. M. M., Caputo, M., Camp, D. M., Reddy, S., & Achenbach, C. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302338 · Cited by 6
Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review
PEREIRA, L. F. T., Tredus, J. G. R., Corá, L. O., Novacki, L. L., Oliveira, G. E. D., Vodiani, M., Dias, I. P., Filho, R. X. V., & Picheth, G. F. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2382077 · Cited by 5
Jiang, J., Lam, K. F., Lau, E. H. Y., Yin, G., Lin, Y., & Cowling, B. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-89043-8 · Cited by 6
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 6
“7% at >4 months postdose 2).(60) In light of these data, PfizerBioNTech administered a 30 mg booster dose to a small group of participants during phase 1 of the ongoing clinical trial (11 participants 18 55 years of age and 12 participated 65 85 years of age).”
BackgroundMarra, A., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Schweizer, M. L., Diekema, D., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J., et al. (2022) · Antimicrobial Stewardship and Healthcare Epidemiology · doi:10.1017/ash.2021.261 · Cited by 4
Bester, J. C. (2022) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10182-y · Cited by 6
“This includes many well-done randomized controlled trials, which is the gold standard in therapeutic trials and in establishing effectiveness (McDonald et al. 2021.; Polack et al. 2020; Thomas et al. 2021).”
BackgroundMethodResultInfluentialBorgonovo, F., Stangalini, C. A., Tinelli, C., Mariani, C., Mileto, D., Cossu, M. V., Abbati, L., Bilardo, L., Gagliardi, G., Cutrera, M., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060018 · Cited by 5
Hong, H., Noh, J. Y., Lee, H., Choi, S., Choi, B., Kim, J. K., & Shin, E. (2022) · Immune Network · doi:10.4110/in.2022.22.e23 · Cited by 5
Hong, L.-Y., Lee, C.-H., & Chiu, I. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.844004 · Cited by 5
“3% of the participants were Asian in a multinational study on the safety and effectiveness of the BNT162b2 mRNA COVID-19 vaccine (13).”
BackgroundHoshida, S., Koeda, N., Hattori, H., Tanaka, M., Tanaka, I., Fukui, H., Fujita, J., Sasaki, Y., & Tamura, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07695-7 · Cited by 7
“Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months.”
MethodInfluentialCaserta, L. C., Martins, M., Cronk, B. D., Anderson, R. R., Eldridge, H., Gallow, D., Kruppa, F., Plocharczyk, E. F., & Diel, D. G. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00563-22 · Cited by 5
Fazio, S., Cosentino, M., Marino, F., Pandolfi, S., Zanolin, E., & Bellavite, P. (2022) · Journal of Pharmacy and Pharmacology Research · doi:10.26502/fjppr.055 · Cited by 5
“However, in actual fact, the authorization studies on COVID-19 vaccines have not provided any evidence of a possible reduction in deaths from COVID-19 [14] since all-cause mortality was not substantially different over a six month period comparing subjects in whom was administered the BNT162b2 vaccine (15 deaths) with…”
BackgroundRamos, L., Hernández-Porto, M., Palau, M. C., Alonso-Abreu, I., Reygosa, C., & Hernández‐Guerra, M. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac228 · Cited by 5
Kelly, N. E. W., Barra, C. D., Shaamile, F., Holland, A., Shaw, L., Mallon, P. W. G., O’Connell, J., Hogan, A. E., & O'Shea, D. B. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01235-8 · Cited by 7
Kim, A., Kim, S., Song, J.-E., Hwang, S., Nam, E., & Kwon, K. T. (2023) · Vaccines · doi:10.3390/vaccines11020363 · Cited by 5
“Contrastingly, the safety results of BNT162b2 phase 1, 2, and 3 clinical trials revealed incidence rates of 78% and 74% for injection site pain after the first and second doses, respectively, and 43% and 58% for fatigue after the first and second doses, respectively [12].”
BackgroundAsashima, H., Kim, D., Wang, K., Lele, N., Buitrago-Pocasangre, N., Lutz, R., Cruz, I., Raddassi, K., Ruff, W. E., Racke, M. K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168102 · Cited by 5
Walory, J., Książek, I., Karyński, M., & Baraniak, A. (2023) · Vaccines · doi:10.3390/vaccines11101578 · Cited by 5
Lang, A.-L., Hohmuth, N., Višković, V., Konigorski, S., Scholz, S. M., Balzer, F., Remschmidt, C., & Leistner, R. (2024) · Journal of Medical Internet Research · doi:10.2196/47070 · Cited by 5
Potts, K. G., Noyce, R. S., Gafuik, C., John, C. M., Todesco, H. M., de Heuvel, E., Favis, N. A., Kelly, M. M., Evans, D. H., & Mahoney, D. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.27.474282 · Cited by 5
Kuzmina, A., Atari, N., Ottolenghi, A., Korovin, D., Cohen-Lass, I., Rosental, B., Rosenberg, E., Mandelboim, M., & Taube, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.26.489630 · Cited by 5
Vashishtha, V. M., & Kumar, P. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2077196 · Cited by 5
“Further, studies have suggested a significant waning of protection against symptomatic Covid-19 with time [6].”
BackgroundDecru, B., Elslande, J. V., Steels, S., Pottelbergh, G. V., Godderis, L., Holm, B. V., Bossuyt, X., Weyenbergh, J. V., Maes, P., & Vermeersch, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098285 · Cited by 5
Biswal, M. R., Roy, S. K., & Singh, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.04.616619 · Cited by 5
“Recently, two authorized COVID-19 vaccines, mRNA-1273 24,25 and BNT162b 26 use LNP to deliver antigen mRNA.”
BackgroundLayton, J. B., Lloyd, P. C., Peetluk, L. S., Jiao, Y., Djibo, D. A., Gruber, J. F., Deng, J., Bui, C. L., Lo, A., Ogilvie, R. P., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320434 · Cited by 4
“Many early, real-world US studies affirmed the real-world effectiveness of COVID-19 vaccines in preventing severe disease [5–12], though some suggested that vaccine effectiveness (VE) waned over time in fully vaccinated individuals [3,7,13–15].”
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 5
“The successful development of mRNA vaccines for coro-navirus infection addressed practical challenges by optimizing the mRNA construct, thereby increasing its stability and expression efficiency [5, 8–10].”
Polypore mushroom mycelia as an adjunct to COVID-19 vaccination: a randomized clinical trial
Saxe, G. A., Smith, C. N., Golshan, S., Shekhtman, T., Bair, Z. J., Beathard, C., Davis, R. A., MacElhern, L., Shubov, A., Slater, D. W., et al. (2026) · BMC Immunology · doi:10.1186/s12865-026-00809-9 · Cited by 4
“Further, Ab levels wane over time, marked by increasing rates of COVID-19 infection within 2–6 months post-vaccination [25, 26].”
Challenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine
Karczmarzyk, K., & Kęsik-Brodacka, M. (2026) · Vaccines · doi:10.3390/vaccines14020173 · Cited by 5
Freund, O., Harish, A., Breslavsky, A., Wand, O., Zacks, N., Bilenko, N., & Bar‐Shai, A. (2023) · Journal of Public Health · doi:10.1093/pubmed/fdad198 · Cited by 4
The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy
Saleh, D., Meng, Z., Johnson, N. A., Baldridge, A. S., Zielinski, A. R., & Choudhury, L. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040104 · Cited by 5
Walach, H., & Klement, R. J. (2024) · Journal of Scientific Exploration · doi:10.31275/20243249 · Cited by 4
Parcesepe, A. M., Nash, D., Shen, J., Kulkarni, S., Zimba, R., You, W., Berry, A., Piltch-Loeb, R. N., Fleary, S. A., Stanton, E., et al. (2024) · Depression and Anxiety · doi:10.1155/2024/9682710 · Cited by 4
“A robust evidence base demonstrates the safety and e ffi cacy of these vaccines in preventing severe COVID-19 illness, hospitalization, and death, and more recently, long COVID-19 [15 – 18].”
Rashiti-Bytyçi, A., Johansson, E. W., Kaçaniku‐Gunga, P., Danis, K., Schoeps, A., Dörre, A., Fetaj, F., & Kalaveshi, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305629 · Cited by 4
Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2
Liu, J., Han, H., Yang, B., Zhang, N., Li, J., Chen, X., Wu, J., Zhao, Y., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1416375 · Cited by 4
Mi, Y., Xu, K., Wang, W., Kong, W., Xu, X., Rong, X., & Tan, J. (2024) · Vaccines · doi:10.3390/vaccines12080927 · Cited by 4
“On the one hand, some studies have reported that the antibody levels declined over time after vaccination [13–15].”
BackgroundSelf-citationHwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4
“18,19 Research showing that booster vaccination restores waning immunity and reduces hospitalization and mortality led to the recommendation that a booster dose be administered after completion of the primary course.”
Omae, Y., Khor, S., Shimada, M., Kawai, Y., Yamaguchi, T., Yagi, M., Ebisawa, M., Takeuchi, J. S., Mizoue, T., Sugiura, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-90787-6 · Cited by 4
Kawasaki, T., Ikegawa, M., & Kawai, T. (2025) · International Immunology · doi:10.1093/intimm/dxaf033 · Cited by 4
Grunau, B. E., Golding, L., Prusinkiewicz, M. A., Asamoah-Boaheng, M., Armour, R., Marquez, A. C., Jassem, A. N., Barakauskas, V., O’Brien, S. F., Drews, S. J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02702-21 · Cited by 4
Lin, Z.-Q., Wu, J., Huang, R., Xie, F., Li, J., Zheng, K., & Zhang, D. (2022) · Vaccines · doi:10.3390/vaccines10040622 · Cited by 4
“For example, the efficacy of BNT162b2 against COVID-19 waned from 95% between 7 days and 2 months to 84% between 4 and 6 months after the second dose [2,3].”
BackgroundAdverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
Nishizawa, T., Jinta, T., Koyamada, R., Uehara, Y., Taki, F., & Arioka, H. (2022) · Journal of General and Family Medicine · doi:10.1002/jgf2.545 · Cited by 4
Acute Hepatitis of Unknown Origin (AHUO)—The Puzzle Ahead
Sergi, C. M. (2022) · Diagnostics · doi:10.3390/diagnostics12051215 · Cited by 4
Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2022) · Nefrología · doi:10.1016/j.nefro.2022.12.006 · Cited by 5
The effects of the Covid-19 vaccine on menstrual disorders in women of reproductive age
Yoosefian, M., Esmaeili, A., Parizi, Z. P., Kermanshahaninezhad, S. O., & Babaki, B. S. (2023) · Journal of Public Health · doi:10.1007/s10389-023-02120-y · Cited by 4
“In the clinical studies of receiving the Covid-19 vaccine, side effects have been observed including ache, redness, and edema at the infusion site as well as pyrexia, headache, fatigue, and muscle aches (Baden et al. 2020; Haimei 2021; Thomas et al. 2021; Voysey et al. 2021).”
Roncati, L., Bartolacelli, G., Galeazzi, C., & Caramaschi, S. (2023) · Pathogens · doi:10.3390/pathogens12121376 · Cited by 6
Dofuor, A. K., Quartey, N. K.-A., Osabutey, A. F., Boateng, B. O., Lutuf, H., Osei, J. H. N., Ayivi-Tosuh, S. M., Aiduenu, A. F., Ekloh, W., Loh, S. K., et al. (2023) · Clinical Pathology · doi:10.1177/2632010x231218075 · Cited by 4
Lee, C., Otunla, A. A., Brennan, I., Aronson, J. K., & Nunan, D. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15992 · Cited by 4
COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)—a Randomized Controlled Clinical Trial
Le, M., Khoury, L., Lu, Y., Prosty, C. J., Cormier, M., Cheng, M. P., Fowler, R., Murthy, S., Tsang, J. L. Y., Ben‐Shoshan, M., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae102 · Cited by 5
Motives for Vaccination Against COVID-19 Among the Ultra-orthodox Jewish Community in Israel
Schiff, M., & Sharon-Lavi, N. (2024) · Journal of Religion and Health · doi:10.1007/s10943-024-02018-3 · Cited by 4
Importance of Examining Incidentality in Vaccine Safety Assessment
Suzumura, Y. (2024) · Vaccines · doi:10.3390/vaccines12050555 · Cited by 4
“For example, Thomas et al. reported the results of a placebo-controlled pivotal efficacy trial evaluated through 6 months after BNT162b2 vaccination [22].”
Result
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.